Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

In absolute terms, there were 0.73 cases of hypoglycaemia per year with insulin icodec, versus 0.27 events for the once-daily drug. Novo Nordisk said that if approved for use, insulin icodec would ...

Paige’s case is by no means an isolated incident ... next person and the next person and they just think ‘I want that’.” Alongside the MHRA, Novo Nordisk, which is the only company manufacturing ...

Although no randomized clinical trials using U-500 insulin have been performed, eight case series (involving ... Actrapid U-500, Novo Nordisk in the United Kingdom [voluntarily withdrawn in ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on ...

Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NYSE:NVO)'s ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s.